Popular on PrZen
- Home Run Pest & Termite Control Launches Monthly Mosquito Service to Help Wylie, Plano, and Rockwall Homeowners Reclaim Their Backyards - 294
- Students Celebrate Earth Month and Learn About the Lifecycle of Trees - 270
- Museum Hack Presents Hacked Gala: A Rebellious Night of Art, Fashion, and Change at the Met - 116
- American Mensa Welcomes 7-Year-Old Savannah Boy - 112
- Artist Séfora Camazano Honored with Prestigious Prize "The New Great Masters in New York" - 104
- Tobu Railway Announces a Price Revision on the "NIKKO PASS All Area" and "NIKKO PASS World Heritage Area," from April 20, 2025 - 104
- Damian Redd's "Caught in a Fantasy" Surpasses 100,000 Views on VEVO/YouTube Following Album Reissue - 103
- Webinar Announcement: Mexico's Evolving AML/CFT Environment: FATF Review and FTO Designations - 102
- Guests Can Save 20 Percent on a Florida Keys Vacation Home Rental with KeysCaribbean's 'Last-Minute Booking Discount' - 101
- Jayson Warner Smith joins the cast of Tulsa King, The Good Daughter and Murdaugh Murders in 2025
Similar on PrZen
- The ROS1ders Announces Recipients of 2024 ROS1+ Cancer Innovation Awards
- WWSG Announces Exclusive Speaking Partnership with Patrick McGee, Author of 'Apple in China'
- Plan Signed to Purchase Kadima Neuropsychiatry Institute as Clinical Treatment Model and Leading Investigative Site Addressing Suicidal Depression
- Tribeca Film Festival Official Podcast Selection Lead Features Hollywood Stars, Focuses On Ending Childhood Lead Poisoning In New York!
- $34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thinner, Less Problematic Than Warfrain: $CVKD
- Pikmykid Launches $100,000 School Safety Grant Giveaway to Support K–12 Schools Across the U.S
- The OpenSSL Corporation and the OpenSSL Foundation Certify Results of Technical Advisory Committee Elections
- Mother's Day Wake-Up Call for Maternal Health: New Initiative Demands Better Postpartum Support
- SlotCycle Joins Association of Gaming Equipment Manufacturers (AGEM) to Advance Sustainable Gaming Solutions
- RWA Infra Development L.L.C. announces the $RWAID token. "$RWAID tokenizing infrastructure for the masses."
First Choice Neurology Partners with NeuroDiscovery AI to Advance Neurological Care and Research
PrZen/33578891
MIAMI - PrZen -- First Choice Neurology is proud to announce a groundbreaking partnership with NeuroDiscovery AI (NDAI), a national leader in artificial intelligence, data analytics, and clinical dashboarding for neurology. This strategic collaboration brings cutting-edge AI capabilities to our practice and connects us with a nationwide prestigious network of leading outpatient neurology groups. Together, we are working to transform the future of neurology by advancing research, optimizing patient outcomes, and elevating standards of care.
Through this collaboration, First Choice Neurology joins a national alliance of leading neurology practices committed to driving innovation in patient care with the world's most extensive longitudinal dataset in neurology. Together, we will utilize AI-powered insights to:
Today, we stand at the forefront of neurological research, armed with:
Advancing Care in Key Neurological Areas
Our partnership with NeuroDiscovery AI allows us to focus on several high-impact areas of neurological research and care:
Multiple Sclerosis (MS) - A chronic autoimmune disorder affecting the central nervous system. With the help of NeuroDiscovery AI, our MS specialists can track disease progression, evaluate treatment efficacy, and explore new therapeutic options more effectively than ever before.
"The quality and volume of information that NDAI can garner from our records is outstanding. This collaboration provides us with powerful tools to better understand disease patterns and personalize MS treatment strategies. Levels of magnitude are greater than I thought possible. It's a major leap forward in how we care for our MS patients."
— Dr. Bernard Gran, Neurologist, First Choice Neurology
Parkinson's Disease (PD) - A progressive neurodegenerative disorder that affects movement, cognition, and quality of life. Through data-driven research, we're identifying new biomarkers and refining care models that improve long-term outcomes for Parkinson's patients.
Alzheimer's Disease (AD) - One of the leading outpatient neurology groups treating Alzheimer's and other forms of dementia, First Choice Neurology is at the forefront of clinical care and research. NeuroDiscovery AI will allow us to analyze large-scale data sets, assess the real-world effectiveness of new medications, and contribute to developing novel therapies.
NeuroDiscovery AI offers clinicians and researchers millions of data points to investigate new treatments for neurological disorders. "Let's say you want to evaluate and identify a group of 100 women, between the ages of 50-65, with a maternal history of dementia, and track their development of cognitive decline. NDAI can generate that data in a minute as opposed to weeks or months. Do you wish to assess associated genetic markers? That would take another minute. And to correlate common MRI patterns would take just another minute." Dr. Jeff Gelblum believes that "this new computer technology will revolutionize clinical research and treatment protocols."
— Dr. Jeff Gelblum, Neurologist and national authority on the treatment of Alzheimer's, First Choice Neurology
Frontotemporal Dementia (FTD) - A lesser-known but equally devastating condition that affects personality, behavior, and language. Through our partnership, we aim to accelerate research into early detection and management, contributing to broader efforts in combating all forms of dementia.
Migraine and Headache Disorders - One of the most common neurological disorders, often misunderstood and underdiagnosed. Our migraine specialists are now equipped with enhanced tools to track patient responses to medications and identify patterns that may lead to more effective, personalized treatments.
Autism and Developmental Disorders - Neurodevelopmental conditions like autism require a highly individualized and evidence-based approach. With this partnership, our child neurologists and neuropsychologists will be able to integrate behavioral data and clinical metrics to improve diagnosis and track developmental progress over time.
Looking Ahead
We believe that the future of neurology lies at the intersection of clinical expertise, innovative technology, and collaborative research. Our partnership with NeuroDiscovery AI marks an exciting step forward in our journey to lead that transformation. We look forward to working with them and changing the world, together.
To learn more about First Choice Neurology, visit https://www.fcneurology.net/
To learn more about NeuroDiscovery AI, visit https://neurodiscovery.ai/
Through this collaboration, First Choice Neurology joins a national alliance of leading neurology practices committed to driving innovation in patient care with the world's most extensive longitudinal dataset in neurology. Together, we will utilize AI-powered insights to:
- Revolutionize patient care through AI and extensive medical data
- Monitor treatment outcomes in real-time
- Accelerate research and clinical trials
- Discover new biomarkers & novel targets
- Improve care coordination and efficiency
Today, we stand at the forefront of neurological research, armed with:
- The world's most extensive longitudinal dataset in neurology
- Partnerships with over 470 leading neurology providers across the US
- A comprehensive database consists of multimodal data extracted from 5 M+ patients
- Cutting-edge AI technology to derive meaningful insights from complex data
Advancing Care in Key Neurological Areas
Our partnership with NeuroDiscovery AI allows us to focus on several high-impact areas of neurological research and care:
Multiple Sclerosis (MS) - A chronic autoimmune disorder affecting the central nervous system. With the help of NeuroDiscovery AI, our MS specialists can track disease progression, evaluate treatment efficacy, and explore new therapeutic options more effectively than ever before.
"The quality and volume of information that NDAI can garner from our records is outstanding. This collaboration provides us with powerful tools to better understand disease patterns and personalize MS treatment strategies. Levels of magnitude are greater than I thought possible. It's a major leap forward in how we care for our MS patients."
— Dr. Bernard Gran, Neurologist, First Choice Neurology
Parkinson's Disease (PD) - A progressive neurodegenerative disorder that affects movement, cognition, and quality of life. Through data-driven research, we're identifying new biomarkers and refining care models that improve long-term outcomes for Parkinson's patients.
Alzheimer's Disease (AD) - One of the leading outpatient neurology groups treating Alzheimer's and other forms of dementia, First Choice Neurology is at the forefront of clinical care and research. NeuroDiscovery AI will allow us to analyze large-scale data sets, assess the real-world effectiveness of new medications, and contribute to developing novel therapies.
NeuroDiscovery AI offers clinicians and researchers millions of data points to investigate new treatments for neurological disorders. "Let's say you want to evaluate and identify a group of 100 women, between the ages of 50-65, with a maternal history of dementia, and track their development of cognitive decline. NDAI can generate that data in a minute as opposed to weeks or months. Do you wish to assess associated genetic markers? That would take another minute. And to correlate common MRI patterns would take just another minute." Dr. Jeff Gelblum believes that "this new computer technology will revolutionize clinical research and treatment protocols."
— Dr. Jeff Gelblum, Neurologist and national authority on the treatment of Alzheimer's, First Choice Neurology
Frontotemporal Dementia (FTD) - A lesser-known but equally devastating condition that affects personality, behavior, and language. Through our partnership, we aim to accelerate research into early detection and management, contributing to broader efforts in combating all forms of dementia.
Migraine and Headache Disorders - One of the most common neurological disorders, often misunderstood and underdiagnosed. Our migraine specialists are now equipped with enhanced tools to track patient responses to medications and identify patterns that may lead to more effective, personalized treatments.
Autism and Developmental Disorders - Neurodevelopmental conditions like autism require a highly individualized and evidence-based approach. With this partnership, our child neurologists and neuropsychologists will be able to integrate behavioral data and clinical metrics to improve diagnosis and track developmental progress over time.
Looking Ahead
We believe that the future of neurology lies at the intersection of clinical expertise, innovative technology, and collaborative research. Our partnership with NeuroDiscovery AI marks an exciting step forward in our journey to lead that transformation. We look forward to working with them and changing the world, together.
To learn more about First Choice Neurology, visit https://www.fcneurology.net/
To learn more about NeuroDiscovery AI, visit https://neurodiscovery.ai/
Source: First Choice Neurology
0 Comments
Latest on PrZen
- The ROS1ders Announces Recipients of 2024 ROS1+ Cancer Innovation Awards
- AUACOM Signs a Statement of Shared Interest with BMCC
- WWSG Announces Exclusive Speaking Partnership with Patrick McGee, Author of 'Apple in China'
- Multi-Billion Dollar Drone Cleaning Market Addressed via New UAE Office, AI Drone and Quantum Computing Solutions in Varied Industries ZenaTech, Inc
- Spac Recovery Co. Files $590 Million Lawsuit Against Blackstone Products, Nomura , Franklin Square, Oaktree et al
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Sparking Disruptive Innovation in Web3
- Plan Signed to Purchase Kadima Neuropsychiatry Institute as Clinical Treatment Model and Leading Investigative Site Addressing Suicidal Depression
- Tribeca Film Festival Official Podcast Selection Lead Features Hollywood Stars, Focuses On Ending Childhood Lead Poisoning In New York!
- Industrial Parts Fittings Champions the Revival of American Manufacturing
- $34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thinner, Less Problematic Than Warfrain: $CVKD
- Pikmykid Launches $100,000 School Safety Grant Giveaway to Support K–12 Schools Across the U.S
- Slotozilla Data Report: Unveiling 2024's Gaming Statistics
- BK Flooring Releases Their Top Reasons to Upgrade Kitchen Tile Flooring in 2025
- The OpenSSL Corporation and the OpenSSL Foundation Certify Results of Technical Advisory Committee Elections
- ROME-ANTICS Unleashed: A Music Video by Sidow Sobrino Transforms Rome into a Living Stage
- Mother's Day Wake-Up Call for Maternal Health: New Initiative Demands Better Postpartum Support
- Southbox Entertainment, FinTech Pioneer & Entrepreneur Jon Gosier Join Psychological Thriller The Dutchman as Financing Partner
- SlotCycle Joins Association of Gaming Equipment Manufacturers (AGEM) to Advance Sustainable Gaming Solutions
- RWA Infra Development L.L.C. announces the $RWAID token. "$RWAID tokenizing infrastructure for the masses."
- Mental Health Awareness Month—Tennessee Enacts Psychotropic Testing Law